Fulcrum therapeutics announces clinical hold on ftx-6058 in sickle cell disease

Cambridge, mass., feb. 24, 2023 (globe newswire) -- fulcrum therapeutics, inc.® (nasdaq: fulc), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that on february 23, 2023, the u.s. food and drug administration (fda) verbally informed the company that it has issued a full clinical hold regarding the investigational new drug (ind) application for ftx-6058 for the potential treatment of sickle-cell disease. the agency indicated that it would provide a formal clinical hold letter to the company within 30 days.
FULC Ratings Summary
FULC Quant Ranking